← Leaderboards
Myron J Levin
University Of Colorado Denver
$1,922,609
Attributed
$3,690,025
Total exposure
11
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $729.2K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,690,025 · 11
By mechanism
U01$3,534,832 · 1
M01$88,860 · 9
P30$66,333 · 1
Top collaborators
- Adriana Weinberg5 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Maria Acena Nagel$8,256,702
- Donald Gilden$19,848,267
- Randall J. Cohrs$10,553,236
- Lee S Newman$61,333,454
- Adriana Weinberg$9,708,858
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsChickenpoxAdaptive Immune ResponseCd8-Positive T-LymphocytesChildhoodChemokineDoseCytokineAllelesAfferent NerveAfferent NeuronsAntigen-Presenting CellsAttenuated VaccinesAttenuatedAdjuvantCellsAdultCellular ImmunityCharacteristicsBiopsyBloodCell Type
Grant awards (18)
PERSISTENCE OF PROTECTION CONFERRED BY SHINGRIX AGAINST HERPES ZOSTER IN OLDER ADULTS$685,272
U01 · FY2023 · AI
PERSISTENCE OF PROTECTION CONFERRED BY SHINGRIX AGAINST HERPES ZOSTER IN OLDER ADULTS$699,825
U01 · FY2022 · AI
PERSISTENCE OF PROTECTION CONFERRED BY SHINGRIX AGAINST HERPES ZOSTER IN OLDER ADULTS$704,995
U01 · FY2021 · AI
PERSISTENCE OF PROTECTION CONFERRED BY SHINGRIX AGAINST HERPES ZOSTER IN OLDER ADULTS$715,495
U01 · FY2020 · AI
PERSISTENCE OF PROTECTION CONFERRED BY SHINGRIX AGAINST HERPES ZOSTER IN OLDER ADULTS$729,245
U01 · FY2019 · AI
Developmental Core$66,333
P30 · FY2008 · AI · contact PI
PACTG P1057: SAFETY AND IMMUNOGENICITY OF FLUMIST IN HIV-INFECTED CHILDREN$9,947
M01 · FY2006 · RR · contact PI
PACTG P1057: SAFETY AND IMMUNOGENICITY OF FLUMIST IN HIV-INFECTED CHILDREN$31,712
M01 · FY2005 · RR
PACTG 1010: ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECT CHILDREN$3,659
M01 · FY2005 · RR
ACTG #265: SAFETY &IMMUNOGENICITY OF VARICELLA VACCINE IN HIV INFECTED CHILDREN$1,218
M01 · FY2005 · RR
Antiretroviral Tx on Body Comp. in HIV-infected Children$1,737
M01 · FY2004 · RR
ACTG #265: Safety &Immunogenicity of Varicella Vaccine in HIV Infected Children$867
M01 · FY2004 · RR
SEROCONVERSION OF SINGLE DOSE/TWO DOSE MEASLES VACCINATION IN HIV INFECTED CHILD$0
M01 · FY2002 · RR
ACTG 247--INCREASED CALORIC FORMULA ON GROWTH &NUTRITION IN HIV INFECTED INFANTS$0
M01 · FY2002 · RR
ACTG 265--SAFETY &IMMUNOGENICITY OF VARICELLA VACCINE IN HIV INFECTED CHILDREN$19,860
M01 · FY2000 · RR
ACTG 185--HIVIG FOR PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$19,860
M01 · FY2000 · RR
SEROCONVERSION OF SINGLE DOSE/TWO DOSE MEASLES VACCINATION IN HIV INFECTED CHILD$0
M01 · FY2000 · RR
ACTG 247--INCREASED CALORIC FORMULA ON GROWTH &NUTRITION IN HIV INFECTED INFANTS$0
M01 · FY2000 · RR